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ABSTRACT: We investigated the effect of
haloperidol and azaperone in drive-net cap-
tured Southern chamois (Rupicapra pyre-
naica). Both tranquilizers have been success-
fully used in a wide range of wild species for
reducing postcapture stress response. During
2005, 39 free-ranging chamois were captured,
randomly injected intramuscularly with halo-
peridol (0.2960.12 mg/kg; n524), azaperone
(1.160.82 mg/kg; n56), or saline (0.5 ml; n59),
and restrained for 3 hr. Heart rate was higher in
the treated chamois; erythrocyte parameters
and total protein concentration decreased over
time owing to splenic sequestration, hemodilu-
tion, vasodilation, and reflex tachycardia. Cre-
atinine, sodium, and chloride remained stable
only in the haloperidol-treated group, suggest-
ing an improvement in renal perfusion. Never-
theless, the azaperone-treated chamois dis-
played higher body temperature, and both
treated groups had higher serum muscular
enzymes than the control group, suggesting
higher muscle stress. These results lead us not
to recommend the use of these tranquilizers—
especially azaperone—as first-choice neurolep-
tics in chamois.
Key words: Acute stress, azaperone,
chamois, drive-net capture, haloperidol.
The Southern chamois (Rupicapra pyre-
naica) is a medium-sized mountain ungu-
late at ‘‘low risk of extinction’’ (Herrero et
al., 2008). This elusive species inhabits
wild, steep mountain environments making
capture by teleanesthesia difficult and
risky; this has been described for other
mountain species (Abderhalden et al.,
1998). Drive-nets have been reported to
be safe (2.1% mortality rate) and efficient
for capturing chamois (Meneguz et al.,
1994; López-Olvera et al., 2009) but stress
must be kept to a minimum in order to
prevent capture myopathy and improve
animal welfare (Spraker, 1993).
The stress response resulting from cap-
ture varies depending on species and
capture method (Kock et al., 1987). Cate-
cholamines and corticosteroids released
during stress, together with prolonged
exertion, induce changes in hematologic,
serum biochemical, and physiologic param-
eters that are proposed stress indicators
(Guyton and Hall, 2006). Physical capture
increases heart rate, body temperature,
erythrocyte (RBC) count, packed-cell vol-
ume (PCV), and serum concentrations of
hemoglobin (HGB), lactate, creatinine,
urea, bilirubin, chloride, potassium, and
muscular enzymes (López-Olvera et al.,
2007). Hyperthermia and lactic acidosis
may end in capture myopathy, one of the
most common complications of wild animal
capture (Williams and Thorne, 1996).
The appropriate use of tranquilizers may
improve chamois welfare (López-Olvera et
al., 2007). Both haloperidol and azaperone
are short-acting neuroleptics belonging to
the butyrophenones, whose tranquilizing
effect is achieved through central dopami-
nergic and peripheral adrenergic blockade.
They may induce hypotension because of
their a-adrenergic blockade action (Plumb,
2002). Haloperidol has been stated to be
effective as a sedative in small and medi-
um-sized antelope species using doses
ranging from 0.06 to 0.45 mg/kg. Azaper-
one has been used in a wide range of wild
herbivores, doses ranging from 0.5 mg/kg
to 2.5 mg/kg (Arnemo et al., 1993; Swan,
1993; Ebedes and Raath, 1999). The most
common side-effects of butyrophenones
are extrapyramidal signs, restlessness, hy-
pertonia, catalepsy, stiffness, tremors, atax-
ia, allotriophagia, and severe hypotension,
normally associated with overdosage
(Booth, 1988). The objective of this study
was to determine the effects of haloperidol
and azaperone in drive-net captured
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proved by the Animal Welfare Committee
of the Universitat Autònoma de Barcelona.
Fifty-one free-ranging adult Pyrenean
chamois (Rupicapra pyrenaica pyrenaica),
a subspecies of Southern chamois, were
captured in eight capture events using
10310-cm mesh drive-nets (Ziboni Orni-
tecnica, Bergamo, Italy) in the national
hunting reserves of Cadı́ (42u189N,
1u549E) and Freser-Setcases (42u229N,
2u099E), Spain, in the spring and fall of
2005. Captures were performed in early
morning to avoid the heat, under similar
environmental conditions. Twelve (eight
azaperone-treated, three haloperidol-
treated, and one control) out of the 51
(24%) captured chamois died at the initial
capture resulting from a combination of
exhaustion and drug overdose (Menta-
berre et al., unpubl. data). These animals
are not included in the study. All released
chamois that were included were identi-
fied with plastic collars, and no additional
mortality was detected after the capture
events.
Once trapped, 39 of the captured
chamois (25 males and 14 females, aged
2–11 yr) were immediately physically
restrained, blindfolded, placed in sack
nets made of 434-cm mesh (Ziboni
Ornitecnica) and randomly selected to
receive intramuscularly one of three treat-
ments: Six animals received 1.160.82 mg/
kg (mean6standard deviation) of azaper-
one (Stressnil, 40 mg/ml; Janssen-Esteve
Laboratories, Barcelona, Spain), 24 ani-
mals received 0.2960.12 mg/kg of halo-
peridol (5 mg/ml; Kern Pharma-Esteve
Laboratories, Barcelona, Spain), and nine
animals acting as controls received 0.5 ml
of saline. Random application of treatment
produced disparity in the size of the
groups.
Both heart rate and rectal temperature
were measured and recorded at 60-sec
intervals for at least 2 hr using recording
devices (Polar Vantage NV and Polar
S710i, Polar Electro Oy, Kempele, Fin-
land and Mätman datalogger, Eltex of
Sweden AB, Almut, Sweden), as previous-
ly described (López-Olvera et al., 2007).
The mean value for every 5-min period
was calculated for statistical analysis.
Blood samples were collected from the
jugular vein at the moment of capture and
each hour thereafter for 3 hr (1, 2, and 3 hr
posttreatment). Hematology was per-
formed by means of an automated laser
analyzer (Advia 120 hematology system,
Bayer, Fernwald, Germany), except white
blood cell differential count, which was
estimated by identifying 200 leukocytes
in blood smears stained with a three-
stage commercial rapid stain (Diff-
QuickH, Quı́mica Clı́nica Aplicada, Am-
posta, Spain), and PCV, which was mea-
sured using the standard microhematocrit
method (Hawksley, Lancing, England).
Blood samples were centrifuged at 1200
3 G for 15 min and serum was stored at
220 C until analyzed by means of an
automated analyzer (Olympus AU400,
Olympus, Tokyo, Japan).
Repeated-measures analyses of variance
were performed to detect significant
differences (P,0.05) between groups and
within groups over time, using the PROC
MIXED procedure of SAS System for
Windows, V9.1 (SAS Institute, Cary,
North Carolina, USA). The main factor
was treatment (azaperone, haloperidol, or
saline), and the repeated factor was time.
Least-square means were used owing to
the unbalanced distribution of animals in
the groups.
Heart rate and rectal temperature de-
creased from the beginning of the monitor-
ing in all groups (Fig. 1). Heart rate was
significantly higher in the azaperone-treated
group (at 15 min) and in the haloperidol-
treated group (at 5–20 min) than in the
control group, and stabilized (i.e., no
significant differences were found between
two consecutive means) at 35 min (haloper-
idol) or 45 min (azaperone). Heart rate did
not stabilize throughout the study period in
the control group, which displayed a higher
interindividual coefficient of variation
(27.2568.04% [mean6SD]) than the treat-
ed groups (azaperone: 24.16612.47%; hal-







d/article-pdf/46/3/923/2240874/0090-3558-46_3_923.pdf by guest on 17 N
ovem
ber 2020
operidol: 22.5065.60%). The haloperidol
group displayed lower temperatures than
the azaperone-treated (at 5–45 min) and the
control (105–150 min) groups. Temperature
stabilized earlier in the control group (at
25 min) than in the treated ones (azaperone,
50 min; haloperidol, 45 min).
Erythrocyte count, PCV, and HGB and
total protein (TP) concentrations de-
creased over time in both treated groups,
which also displayed lower values of these
parameters from 1 hr posttreatment on-
ward. Serum creatinine concentration
increased in the control and the azaper-
one-treated, whereas chloride concentra-
tion increased only in the control group.
The haloperidol-treated group displayed
lower values of serum creatinine, chloride,
and sodium concentrations than the con-
trol group from 2 hr posttreatment on-
ward. Both treated groups displayed a
stronger increase and had higher values of
aspartate aminotransferase (AST) and
creatine kinase (CK) than the control
group at 3 hr posttreatment (Table 1).
The remaining parameters (WBC, serum
cortisol, glucose, cholesterol, triglycerides,
lactate, bilirubin, and urea concentrations
and alkaline phosphatase activity) did not
differ between treatments. Three animals
receiving high doses of haloperidol
(0.38 mg/kg) and azaperone (1.69 mg/kg
and 2.5 mg/kg) had extrapyramidal signs,
opistotonos, trembling, and tremors.
Heart rate is considered an objective
way of assessing the status of the auto-
nomic nervous system when confronted
with stressors (Hopster and Blokhuis,
1994). Nevertheless, it can be influenced
by numerous factors, with some authors
indicating its physiologic variability as a
better stress indicator than heart rate itself
(Porges, 1985). Red deer (Cervus elaphus)
treated with phenothiazines also displayed
a higher heart rate than control animals
(Diverio et al., 1996), which was attributed
to the reflex tachycardia secondary to
hypotension caused by the tranquilizers
(Plumb, 2002). The lack of stabilization of
heart rate record in the control group, and
the lower interindividual coefficients of
variation in the tranquilized chamois
suggest a more homogeneous response
induced by the tranquilizers.
Physical activity and stress-induced
hyperthermia increase body temperature
in physically captured and restrained
animals; this is an anticipatory response
that can increase temperature by 1–1.5 C
in the first 10 min (Bakken et al., 1999).
Thus, body temperature was already
increased and it was starting to decline
when monitoring began in our study.
Because of this, tranquilizers would only
modulate hyperthermia, but not prevent
it. The later stabilization of temperature in
both treated groups (Fig. 1) could be due
to a lack of effect of the tranquilizers over
central thermoregulation, as previously
reported in wildebeest (Connochaetes
taurinus) and domestic goats (Capra
hircus) for haloperidol (Fick et al., 2006
and 2007). Azaperone seemed to worsen
hyperthermia probably due to paradoxical
excitement (Ebedes and Raath, 1999).
FIGURE 1. Mean heart rate and rectal tempera-
ture of captured chamois. C5control, H5haloperi-
dol, and A5azaperone. Arrows indicate stabilization
of different treatment groups. C* indicates stabiliza-
tion of control group in the study of López-Olvera et
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However, the lower temperature values of
the haloperidol-treated group at the end
of the monitoring period could be related
to vasodilation-induced heat dissipation, as
previously reported for phenothiazines
(López-Olvera et al. 2006b, 2007).
Splenic contraction and peripheral va-
soconstriction caused by the catechol-
amines on a-adrenergic receptors in the
smooth muscle of the splenic capsule and
blood vessels induce an increase in RBC
count, PCV, HGB, and TP (Plumb, 2002).
These parameters decreased only in the
treated groups, probably due to the a-
adrenergic blockade caused by the tran-
quilizers, inducing vasodilation, secondary
hemodilution, and splenic sequestration of
RBCs (Jain, 1993). The results observed
for serum creatinine, chloride, sodium,
and potassium concentrations could also
be explained by vasodilation of renal
arterioles and improvement of renal per-
fusion induced mainly by haloperidol and,
to a lesser extent, azaperone. This effect
has been previously reported in chamois
tranquilized with acepromazine (López-
TABLE 1. Mean hematologic and serum biochemical values of the captured chamois. Different letters (A, B,
C, D) indicate statistically significant differences (P,0.05) between means within each treatment group
(rows). Different italicized numbers (1, 2) indicate statistically significant differences (P,0.05) between
means of different treatment groups within each time (columns). Reference values (central 95% interval) for





et al. 2006a) Treatment Time 0 1 hr 2 hr 3 hr
RBC count
(31012/l)
12.12–17.20 Control 14.98 15.36 1 15.05 1 14.66
Haloperidol 14.38 A 13.52 B2 13.71 B2 13.87 B
Azaperone 14.75 A 13.75 B 13.32 B2 13.85
PCV (l/l) 0.43–0.56 Control 0.471 0.473 0.471 1 0.465
Haloperidol 0.468 A 0.440 B 0.439 B 0.443 B
Azaperone 0.465 A 0.431 B 0.413 B2 0.441
Hemoglobin
(g/l)
147.0–183.8 Control 178.2 180.8 181.0 1 176.4
Haloperidol 176.0 A 164.7 B 165.1 B2 166.1 B
Azaperone 175.8 A 165.2 B 159.0 B2 167.0
Total protein
(g/l)
53–86 Control 66.93 67.89 1 66.30 1 69.59 1
Haloperidol 65.07 A 60.39 B2 57.96 B2 57.81 B2
Azaperone 63.64 A 57.98 B2 59.15 58.65 2
CK (IU/l) 254–2,795 Control 2,801.35 A 5,787.59 7,188.96 B 10,655.21 B1
Haloperidol 2,093.21 A 7,562.67 B 15,170.52 C 18,160.61 D
Azaperone 1,293.66 A 6,939 B 12,531.65 C 19,252.68 D2
AST (IU/l) 134–475 Control 326.20 A 354.13 A,B 364 B,C 493.13 C
Haloperidol 297.59 A 447.76 B 670.24 C 847.36 D
Azaperone 220.59 A 475.17 B 655 C 817.33 D
Creatinine
(mmol/l)
70.72–159.12 Control 136.93 A 154.92 B 161 B1 167.96 B1
Haloperidol 127.79 130.05 131.96 2 129.49 2
Azaperone 133.85 155.73 157.65 153.37
Chloride
(mmol/l)
98.4–127.1 Control 100.19 A 104.10 103.38 109.30 B1
Haloperidol 102.44 102.61 103.04 101.87 2
Azaperone 98.49 102.35 105.58 103.40
Sodium
(mmol/l)
122–169 Control 140.91 142.85 140.55 147.44 1
Haloperidol 143.47 140.98 139.58 137.44 2
Azaperone 140.03 141.52 143.87 140.85
Potassium
(mmol/l)
3.9–7.2 Control 5.61 5.75 A 5.55 4.92 B
Haloperidol 5.93 A 5.30 B 4.94 C 4.49 D
Azaperone 5.98 A 5.34 B 4.95 B,C 4.30 C
a RBC 5 erythrocyte; PCV 5 packed-cell volume; CK 5 creatine kinase; AST 5 aspartate aminotransferase; IU 5
international units.
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Olvera et al., 2007). The leukogram
followed a biphasic pattern characteristic
of stress, with initial lymphocytic leukocy-
tosis due to epinephrine and then corti-
costeroid-induced leukocytosis with neu-
trophilia and lymphopenia (Jain, 1993).
Serum activities of lactate dehydroge-
nase, alanine aminotransferase, and, espe-
cially, CK and AST are good predictors of
capture myopathy (Williams and Thorne,
1996). They increase due to damage
related to poor tissue perfusion induced
by catecholamine vasoconstriction, which
increases muscle-cell permeability, de-
creases heat dissipation, and causes hyp-
oxia. The stronger increase and the higher
values observed in the treated chamois
could be due to higher muscle stress
caused by the appearance of adverse
effects of butyrophenones, such as extra-
pyramidal signs, restlessness, isotonic con-
tractions, allotriophagia, and trembling or
stiffness (Ebedes and Raath, 1999).
To summarize, haloperidol demonstrat-
ed some effective action in inhibiting the
sympathetic-adrenal-medulla axis, as sug-
gested by heart rate, and improved renal
function during stress response, as shown
by creatinine, chloride, sodium, and po-
tassium, but azaperone was not as protec-
tive. The higher increase of serum mus-
cular enzyme activity in both tranquillizer-
treated groups suggests that they would
not prevent exertional myopathy. Taken as
a whole, the results suggest a low safety
margin of butyrophenones in this species.
Because neither haloperidol nor azaper-
one improved the effects of acepromazine
(López-Olvera et al., 2007) we can not
recommend their use at the doses assessed
in this study as first-choice neuroleptics in
chamois. Additionally, because better re-
sults have been observed with butyrophe-
nones in other species, the observed
sensitivity could be characteristic of the
tribe Rupicaprini, and it should be taken
into account before using butyrophenones
with other species of this tribe.
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LÓPEZ-OLVERA, J. R., I. MARCO, J. MONTANE, AND S.
LAVIN. 2006a. Haematological and serum bio-
chemical values of southern chamois (Rupicapra
pyrenaica). Veterinary Record 158: 479–484.
———, ———, ———, AND ———. 2006b. Trans-
port stress in Southern chamois (Rupicapra
pyrenaica) and its modulation by acepromazine.
Veterinary Journal 172: 347–355.
———, ———, ———, E. CASAS-DIAZ, AND S. LAVIN.
2007. Effects of acepromazine on the stress
response in Southern chamois (Rupicapra pyr-
enaica) captured by means of drive-nets. Cana-
dian Journal of Veterinary Research 71: 41–51.
———, ———, ———, ———, G. MENTABERRE,
AND S. LAVIN. 2009. Comparative evaluation of
effort, capture and handling effects of drive nets
to capture roe deer (Capreolus capreolus),
southern chamois (Rupicapra pyrenaica) and
Spanish ibex (Capra pyrenaica). European
Journal of Wildlife Research 55: 193–202. doi:
10.1007/s10344-008-0232-5.
MENEGUZ, P. G., L. ROSSI, AND D. DE MENEGHI. 1994.
Esperience di cattura de caprioli (Capreolus
capreolus) e di camosci (Rupicapra rupicapra)
con reti verticali. Bulletin d’Information sur la
Pathologie des Animaux Sauvages 11: 107–114.
PLUMB, D. C. 2002. Veterinary drug handbook. 4th
Edition. Iowa State University Press, Ames,
Iowa, 972 pp.
PORGES, S. W. 1985. Spontaneous oscillations in heart
rate: Potential index of stress. In Animal stress,
G. P. Moberg (ed.). American Physiological
Society, Bethesda, Maryland, pp. 97–112.
SPRAKER, T. R. 1993. Stress and capture myopathy. In
Zoo and wild animal medicine. Current therapy
3, M. E. Fowler (ed.). W. B. Saunders Company,
Philadelphia, Pennsylvania, pp. 481–488.
SWAN, G. E. 1993. Drugs used for the immobiliza-
tion, capture and translocation of wild animals.
In The capture and care manual. Capture, care,
accommodation and transportation of wild Afri-
can animals, A. E. McKenzie (ed.). Wildlife
Decision Support Services and the South African
Veterinary Foundation, Pretoria, South Africa,
pp. 2–64.
WILLIAMS, E. S., AND E. T. THORNE. 1996. Exertional
myopathy (capture myopathy). In Noninfectious
diseases of wildlife. 2nd Edition, A. Fairbrother,
L. N. Locke, and G. L. Hoff (eds.). Iowa State
University Press, Ames, Iowa, pp. 181–193.
Submitted for publication 12 May 2008.
Accepted 2 December 2009.







d/article-pdf/46/3/923/2240874/0090-3558-46_3_923.pdf by guest on 17 N
ovem
ber 2020
